SCHEMBL4152058

SCHEMBL4152058

CCOc1cc(C)ncc1NC(=O)c1ccnc2[nH]c(-c3ccc(N4CCN(C)CC4)cc3)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 5/20 0.45
GSK3A P49840 1/20 0.45
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 2/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
NR4A1 P22736 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SLCO2B1 O94956 1/20 0.41
GLA P06280 1/20 0.41
RECQL P46063 1/20 0.41
BLM P54132 1/20 0.41
BCL2L1 Q07817 1/20 0.41
SLCO1B3 Q9NPD5 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.41
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161485 0.90 GSK3B (0.57) GSK3BGSK3AMAPTSMN1; SMN2MEN1
SCHEMBL4165085 0.89 GSK3B (0.45) GSK3BGSK3ATNKSPARP1TNKS2
SCHEMBL4161481 0.85 GSK3B (0.61) GSK3BGSK3AMEN1KMT2A
SCHEMBL4160778 0.83 GSK3B (0.59) GSK3BGSK3AMAPTSMN1; SMN2KMT2A
SCHEMBL4152659 0.83 GSK3B (0.44) GSK3BGSK3AMAPTKMT2AALDH1A1
SCHEMBL4152839 0.82 GSK3B (0.58) GSK3BGSK3AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4153749 0.82 GSK3B (0.46) GSK3BGSK3AMEN1KMT2ALMNA
SCHEMBL4145195 0.82 GSK3B (0.51) GSK3BGSK3AMAPTSMN1; SMN2KMT2A
SCHEMBL4145735 0.82 GSK3B (0.53) GSK3BSMN1; SMN2CYP2C19LCKKDR
SCHEMBL4165153 0.82 GSK3B (0.52) GSK3BGSK3ATNKSPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885GSK3A 2/4885MAPT 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.